Cargando…
Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria
BACKGROUND: Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tubercu...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364363/ https://www.ncbi.nlm.nih.gov/pubmed/25781958 http://dx.doi.org/10.1371/journal.pone.0120161 |
_version_ | 1782362060791742464 |
---|---|
author | Avong, Yohanna Kamabi Isaakidis, Petros Hinderaker, Sven Gudmund Van den Bergh, Rafael Ali, Engy Obembe, Bolajoko Oladunni Ekong, Ernest Adebamowo, Clement Ndembi, Nicaise Okuma, James Osakwe, Adeline Oladimeji, Olanrewaju Akang, Gabriel Obasanya, Joshua Olusegun Eltayeb, Osman Agbaje, Aderonke Vivian Abimiku, Alash’le Mensah, Charles Olalekan Dakum, Patrick Sunday |
author_facet | Avong, Yohanna Kamabi Isaakidis, Petros Hinderaker, Sven Gudmund Van den Bergh, Rafael Ali, Engy Obembe, Bolajoko Oladunni Ekong, Ernest Adebamowo, Clement Ndembi, Nicaise Okuma, James Osakwe, Adeline Oladimeji, Olanrewaju Akang, Gabriel Obasanya, Joshua Olusegun Eltayeb, Osman Agbaje, Aderonke Vivian Abimiku, Alash’le Mensah, Charles Olalekan Dakum, Patrick Sunday |
author_sort | Avong, Yohanna Kamabi |
collection | PubMed |
description | BACKGROUND: Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria. METHOD: This was a retrospective, observational cohort study, using pharmacovigilance data systematically collected at all MDR-TB treatment centers in Nigeria. Characteristics of AEs during the intensive phase treatment were documented, and risk factors for development of AEs were assessed. RESULTS: Four hundred and sixty patients were included in the analysis: 62% were male; median age was 33 years [Interquartile Range (IQR):28–42] and median weight was 51 kg (IQR: 45–59). Two hundred and three (44%) patients experienced AEs; four died of conditions associated with SLD AEs. Gastro-intestinal (n = 100), neurological (n = 75), ototoxic (n = 72) and psychiatric (n = 60) AEs were the most commonly reported, whereas ototoxic and psychiatric AEs were the most debilitating. Majority of AEs developed after 1–2 months of therapy, and resolved in less than a month after treatment. Some treatment centers were twice as likely to report AEs compared with others, highlighting significant inconsistencies in reporting at different treatment centers. Patients with a higher body weight had an increased risk of experiencing AEs. No differences were observed in risk of AEs between HIV-infected and uninfected patients. Similarly, age was not significantly associated with AEs. CONCLUSION: Patients in the Nigerian MDR-TB cohort experienced a wide range of AEs, some of which were disabling and fatal. Early identification and prompt management as well as standardized reporting of AEs at all levels of healthcare, including the community is urgently needed. Safer regimens for drug-resistant TB with the shortest duration are advocated. |
format | Online Article Text |
id | pubmed-4364363 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-43643632015-03-23 Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria Avong, Yohanna Kamabi Isaakidis, Petros Hinderaker, Sven Gudmund Van den Bergh, Rafael Ali, Engy Obembe, Bolajoko Oladunni Ekong, Ernest Adebamowo, Clement Ndembi, Nicaise Okuma, James Osakwe, Adeline Oladimeji, Olanrewaju Akang, Gabriel Obasanya, Joshua Olusegun Eltayeb, Osman Agbaje, Aderonke Vivian Abimiku, Alash’le Mensah, Charles Olalekan Dakum, Patrick Sunday PLoS One Research Article BACKGROUND: Adverse events (AEs) of second line anti-tuberculosis drugs (SLDs) are relatively well documented. However, the actual burden has rarely been described in detail in programmatic settings. We investigated the occurrence of these events in the national cohort of multidrug-resistant tuberculosis (MDR-TB) patients in Nigeria. METHOD: This was a retrospective, observational cohort study, using pharmacovigilance data systematically collected at all MDR-TB treatment centers in Nigeria. Characteristics of AEs during the intensive phase treatment were documented, and risk factors for development of AEs were assessed. RESULTS: Four hundred and sixty patients were included in the analysis: 62% were male; median age was 33 years [Interquartile Range (IQR):28–42] and median weight was 51 kg (IQR: 45–59). Two hundred and three (44%) patients experienced AEs; four died of conditions associated with SLD AEs. Gastro-intestinal (n = 100), neurological (n = 75), ototoxic (n = 72) and psychiatric (n = 60) AEs were the most commonly reported, whereas ototoxic and psychiatric AEs were the most debilitating. Majority of AEs developed after 1–2 months of therapy, and resolved in less than a month after treatment. Some treatment centers were twice as likely to report AEs compared with others, highlighting significant inconsistencies in reporting at different treatment centers. Patients with a higher body weight had an increased risk of experiencing AEs. No differences were observed in risk of AEs between HIV-infected and uninfected patients. Similarly, age was not significantly associated with AEs. CONCLUSION: Patients in the Nigerian MDR-TB cohort experienced a wide range of AEs, some of which were disabling and fatal. Early identification and prompt management as well as standardized reporting of AEs at all levels of healthcare, including the community is urgently needed. Safer regimens for drug-resistant TB with the shortest duration are advocated. Public Library of Science 2015-03-17 /pmc/articles/PMC4364363/ /pubmed/25781958 http://dx.doi.org/10.1371/journal.pone.0120161 Text en https://creativecommons.org/publicdomain/zero/1.0/ This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration, which stipulates that, once placed in the public domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. |
spellingShingle | Research Article Avong, Yohanna Kamabi Isaakidis, Petros Hinderaker, Sven Gudmund Van den Bergh, Rafael Ali, Engy Obembe, Bolajoko Oladunni Ekong, Ernest Adebamowo, Clement Ndembi, Nicaise Okuma, James Osakwe, Adeline Oladimeji, Olanrewaju Akang, Gabriel Obasanya, Joshua Olusegun Eltayeb, Osman Agbaje, Aderonke Vivian Abimiku, Alash’le Mensah, Charles Olalekan Dakum, Patrick Sunday Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria |
title | Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria |
title_full | Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria |
title_fullStr | Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria |
title_full_unstemmed | Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria |
title_short | Doing No Harm? Adverse Events in a Nation-Wide Cohort of Patients with Multidrug-Resistant Tuberculosis in Nigeria |
title_sort | doing no harm? adverse events in a nation-wide cohort of patients with multidrug-resistant tuberculosis in nigeria |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4364363/ https://www.ncbi.nlm.nih.gov/pubmed/25781958 http://dx.doi.org/10.1371/journal.pone.0120161 |
work_keys_str_mv | AT avongyohannakamabi doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT isaakidispetros doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT hinderakersvengudmund doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT vandenberghrafael doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT aliengy doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT obembebolajokooladunni doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT ekongernest doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT adebamowoclement doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT ndembinicaise doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT okumajames doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT osakweadeline doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT oladimejiolanrewaju doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT akanggabriel doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT obasanyajoshuaolusegun doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT eltayebosman doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT agbajeaderonkevivian doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT abimikualashle doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT mensahcharlesolalekan doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria AT dakumpatricksunday doingnoharmadverseeventsinanationwidecohortofpatientswithmultidrugresistanttuberculosisinnigeria |